Cytokinetics draws new Buy from Citi on aficamten potential
Cytokinetics (CYTK) was initiated by Citi analysts with a Buy rating, citing potential FDA approval for its lead asset ...
Citi sets $86 price target on Cytokinetics stock with buy rating
Citi initiated coverage on Cytokinetics (NASDAQ:CYTK) with a Buy rating and an $86.00 price target, representing significant upside from the current price of $46.17. The firm's analysts highlighted ...
Roblox downgraded, Pinterest upgraded: Wall Street’s top analyst calls
The most talked about and market moving research calls around Wall Street are now in one place. Here are today’s research calls that investors ...